doi: 10.1177/1559827618785554
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Many of our clients notice a substantial reduction in appetite, making it easier to feel satisfied with smaller, healthier meals
This is because the body is adjusting to the medications effects
Instead, it can be a reaction as your body rapidly loses weight from the treatment
It just means that the predominant active side of the fire is not actively growing," Johnson explained